Arthur E. Frankel
Wake Forest University
161 Papers
3K Citations
Arthur E. Frankel is an academic researcher from Wake Forest University. The author has contributed to research in topics: Diphtheria toxin & Fusion protein. The author has an hindex of 46, co-authored 156 publications. Previous affiliations of Arthur E. Frankel include Duke University & University of Texas MD Anderson Cancer Center.
Chat about Author
Papers
•Journal Article
Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.
Y Xu,D C Gaudette,J D Boynton,Arthur E. Frankel,Xianjun Fang,Ajay Sharma,Jean A. Hurteau,Graham Casey,A Goodbody,A Mellors +9 more
TL;DR: Purified OCAF, at concentrations similar to those present in ascites from ovarian cancer patients, was sufficient to induce proliferation of ovarian cancer cells, as indicated by thymidine incorporation, reduction of 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide, or colony formation.
363
Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor.
Arthur E. Frankel,J. Ramage,Melanie Kiser,Richard L. Alexander,Gregory L. Kucera,Mark Steven Miller +5 more
TL;DR: A series of novel, biologically active DT(388)IL3 fusion proteins for potential therapy of patients with receptor positive myeloid leukemias are reported.
•Journal Article
Phase I Trial of a Novel Diphtheria Toxin/Granulocyte Macrophage Colony-stimulating Factor Fusion Protein (DT388GMCSF) for Refractory or Relapsed Acute Myeloid Leukemia
TL;DR: DT388GMCSF can produce complete and partial remissions in patients with chemotherapy-resistant acute myeloid leukemia, but methods to prevent liver injury are needed before more widespread application of this novel agent.
135
Immunotoxins: a clinical review of their use in the treatment of malignancies.
TL;DR: The most successful clinical application of immunotoxins has been in the depletion of T cells from allogeneic bone marrow grafts to prevent graft-versus-host disease (GVHD).
126
Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias.
Arthur E. Frankel,James A. McCubrey,Mark Steven Miller,Stephen J. Delatte,J. Ramage,M. Kiser,Gregory L. Kucera,Richard L. Alexander,M. Beran,Edward P. Tagge,Robert J. Kreitman,Donna E. Hogge +11 more
TL;DR: The sensitivity to DTLIL3 of leukemic progenitors from a number of acute phase CML patients suggests that this agent could have therapeutic potential for some patients with this disease.
124